Immunocore Holdings plc (IMCR) · Insider trading

What Immunocore Holdings's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months

0 insiders, 0 trades

Sold, 12 months

$5.63M

4 insiders, 89% under a plan

Net, 12 months

−$5.63M

bought less sold

Latest filing

2026-02-19

filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

Bought Sold Largest month: $23.99M

Who traded, two years

Insider	Bought	Sold	Trades	Last trade	Holds after
Baker JulianDirector	$23.99M	–	4	2025-03-17	–
Berman David MHEAD OF R&D	–	$10.02M	14	2026-02-18	5,859
Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER	–	$371,184	1	2026-02-18	12,343
St Leger Tina AmberCHIEF HR OFFICER	–	$32,350	1	2026-02-18	1,119
Goll JohnSVP, FINANCE & CAO	–	$22,580	1	2026-02-18	653

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

Date	Insider	Trade	Shares	Price	Value	Holds after	Filing
2026-02-18	Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER	Sale	11,474	32.35	$371,184	12,343	Form 4
2026-02-18	Goll JohnSVP, FINANCE & CAO	Sale	698	32.35	$22,580	653	Form 4
2026-02-18	Berman David MHEAD OF R&D	Sale	5,965	32.35	$192,968	5,859	Form 4
2026-02-18	St Leger Tina AmberCHIEF HR OFFICER	Sale	1,000	32.35	$32,350	1,119	Form 4
2025-12-05	Berman David MHEAD OF R&D	Saleplan	572	40.14	$22,960	0	Form 4
2025-12-04	Berman David MHEAD OF R&D	Saleplan	31,341	40.26	$1.26M	0	Form 4
2025-11-28	Berman David MHEAD OF R&D	Saleplan	5,521	40.09	$221,337	0	Form 4
2025-11-26	Berman David MHEAD OF R&D	Saleplan	69,404	40.12	$2.78M	0	Form 4
2025-11-25	Berman David MHEAD OF R&D	Saleplan	18,020	40.03	$721,341	0	Form 4
2025-11-24	Berman David MHEAD OF R&D	Saleplan	100	40.00	$4,000	0	Form 4
2025-09-30	Berman David MHEAD OF R&D	Saleplan	61,849	35.23	$2.18M	0	Form 4
2025-09-15	Berman David MHEAD OF R&D	Saleplan	200	35.01	$7,002	0	Form 4
2025-09-12	Berman David MHEAD OF R&D	Saleplan	21,232	35.63	$756,496	1,300	Form 4
2025-09-12	Berman David MHEAD OF R&D	Saleplan	1,300	36.31	$47,203	0	Form 4
2025-09-11	Berman David MHEAD OF R&D	Saleplan	19,081	36.28	$692,259	0	Form 4
2025-09-10	Berman David MHEAD OF R&D	Saleplan	30,138	36.12	$1.09M	1,200	Form 4
2025-09-10	Berman David MHEAD OF R&D	Saleplan	1,200	36.77	$44,124	0	Form 4
2025-03-17	Baker JulianDirectorwith Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (gp) LLC	Buyindirect	60,110	29.74	$1.79M	170,007	Form 4
2025-03-17	Baker JulianDirectorwith Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (gp) LLC	Buyindirect	646,290	29.74	$19.22M	2,051,711	Form 4
2025-03-17	Baker JulianDirectorwith Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (gp) LLC	Buyindirect	8,589	29.56	$253,891	178,596	Form 4
2025-03-17	Baker JulianDirectorwith Baker Felix, Baker Bros. Advisors LP, Baker Brothers Life Sciences LP, 667, L.P., Baker Bros. Advisors (gp) LLC	Buyindirect	92,349	29.56	$2.73M	2,144,060	Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

15 × option exercise

Show them

Date	Insider	What	Shares	Price	Holds after	Filing
2026-02-17	Jallal BahijaDirector, CHIEF EXECUTIVE OFFICER	Option exercise M	+23,817	–	23,817	Form 4
2026-02-17	Goll JohnSVP, FINANCE & CAO	Option exercise M	+1,351	–	1,351	Form 4
2026-02-17	Berman David MHEAD OF R&D	Option exercise M	+11,824	–	11,824	Form 4
2026-02-17	St Leger Tina AmberCHIEF HR OFFICER	Option exercise M	+2,119	–	2,119	Form 4
2025-12-05	Berman David MHEAD OF R&D	Option exercise M	+572	17.46	572	Form 4
2025-12-04	Berman David MHEAD OF R&D	Option exercise M	+31,341	17.46	31,341	Form 4
2025-11-28	Berman David MHEAD OF R&D	Option exercise M	+5,521	17.46	5,521	Form 4
2025-11-26	Berman David MHEAD OF R&D	Option exercise M	+69,404	17.46	69,404	Form 4
2025-11-25	Berman David MHEAD OF R&D	Option exercise M	+18,020	17.46	18,020	Form 4
2025-11-24	Berman David MHEAD OF R&D	Option exercise M	+100	17.46	100	Form 4
2025-09-30	Berman David MHEAD OF R&D	Option exercise M	+61,849	17.46	61,849	Form 4
2025-09-15	Berman David MHEAD OF R&D	Option exercise M	+200	17.46	200	Form 4
2025-09-12	Berman David MHEAD OF R&D	Option exercise M	+22,532	17.46	22,532	Form 4
2025-09-11	Berman David MHEAD OF R&D	Option exercise M	+19,081	17.46	19,081	Form 4
2025-09-10	Berman David MHEAD OF R&D	Option exercise M	+31,338	17.46	31,338	Form 4

How to read it

Buy, sale: Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan: A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after: The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value: Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Immunocore Holdings's scores and multiples ›